Ildong Pharmaceutical , Ltd. EBIT

The latest EBIT for 249420.KS is $-28B as of June 2026. That compares with $57B in the prior-year period — down 148.5% year over year. That is below the sector sector average of $2.6T. Investors often review this figure alongside Ildong Pharmaceutical , Ltd.'s historical trend and sector peers before judging valuation or financial health.

Over the past year, 249420.KS's EBIT moved from $57B to $-28B — a 148.5% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Ildong Pharmaceutical , Ltd.'s operating scale or balance-sheet position.

Against its sector companies, 249420.KS currently prints $-28B for EBIT, while the sector average sits near $2.6T. That is roughly 101.1% below the sector mean. Large gaps often invite a closer look at Ildong Pharmaceutical , Ltd.'s growth, margins, and balance sheet.

A EBIT figure of $-28B for 249420.KS is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $2.6T. Explore the charts below for those layers of context.

After noting 249420.KS's EBIT ($-28B), review year-over-year change from $57B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.